<DOC>
	<DOCNO>NCT01646762</DOCNO>
	<brief_summary>This phase II trial study well paclitaxel albumin-stabilized nanoparticle formulation work treat patient multiple myeloma return respond treatment . Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth cancer cell , either kill cell , stop dividing , stop spreading .</brief_summary>
	<brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate efficacy ( overall response rate ) single agent nab-paclitaxel ( Abraxane ) ( paclitaxel albumin-stabilized nanoparticle formulation ) patient relapse refractory multiple myeloma . SECONDARY OBJECTIVES : I . To evaluate adverse event associate use single agent nab-paclitaxel ( Abraxane ) patient relapse refractory multiple myeloma . II . To evaluate overall survival , time progression , duration response among patient relapse refractory multiple myeloma undergo treatment single agent nab-paclitaxel ( Abraxane ) . OUTLINE : Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously ( IV ) 30 minute day 1 , 8 , 15 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3-6 month 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Absolute neutrophil count &gt; = 500/mm^3 Platelet count &gt; = 25000/mm^3 Hemoglobin &gt; = 6 g/dL Total bilirubin = &lt; 2.5 X institutional upper limit normal ( ULN ) Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) = &lt; 5 X ULN Serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; 5 X ULN Creatinine = &lt; 3 mg/dL Patients relapse refractory myeloma &gt; = 3 line prior therapy Measurable disease multiple myeloma define least ONE following : Serum monoclonal protein &gt; = 1.0 g/dL &gt; 200 mg monoclonal protein urine 24 hour electrophoresis Serum immunoglobulin free light chain &gt; = 10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio Ability understand willingness sign write informed consent document Negative ( serum ) pregnancy test do = &lt; 7 day prior registration , woman childbearing potential ; NOTE : Should woman become pregnant suspect pregnant participating study , inform treat physician immediately Willing return enrol institution ( Mayo Clinic Arizona ) followup study treatment Myelosuppressive therapy myeloma = &lt; 14 day prior registration recover acute reversible adverse event due agent administer &gt; 21 day earlier Other concurrent chemotherapy , radiotherapy , ancillary therapy consider investigational ; NOTE : Bisphosphonates allow protocol treatment ; patient may receive stable dos corticosteroid maximum dose 10 mg prednisone per day give disorder lymphoma rheumatoid arthritis , polymyalgia rheumatica adrenal insufficiency , asthma Other active malignancy = &lt; 3 year prior registration ; EXCEPTIONS : Nonmelanotic skin cancer carcinomainsitu cervix ; NOTE : If history prior malignancy , must receive specific treatment ( i.e . investigational therapy , antineoplastic therapy , etc . ) cancer Any follow : Pregnant woman woman reproductive ability unwilling use effective contraception Nursing woman NOTE : breastfeeding discontinue mother treat nabpaclitaxel ( AbraxaneÂ® ) Men unwilling use condom ( even undergone prior vasectomy ) intercourse woman , take drug 28 day stop treatment Other comorbidity would interfere patient 's ability participate trial , e.g . uncontrolled infection , uncompensated heart lung disease Patients &gt; = grade 2 peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>